- Home
- / TiumBio
TiumBio
Stock Price
₩5.9 K
2024-10-29
Market Capitalization
₩138.5 B
2024-10-29
Revenue
₩6.8 B
FY, 2024
TiumBio Summary
Company Summary
- Overview
- TiumBio (주식회사 티움바이오) is a drug discovery company. It develops treatments for cancer, hemophilia, type 2 diabetes, idiopathic pulmonary fibrosis (IPF), and other diseases.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- Seongnam, KR | view all locations
- Website
- http://www.tiumbio.com/en/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Hyun-sil Ko, CFO
In-young Song, CRO of Biopharmaceuticals
LocationsView all
1 location detected
Seongnam, 경기도 HQ
Korea (Republic of)
6F, Pangyo IT Center, 30 Changup-ro 40 beon-gil, Sujeong-gu
TiumBio Financials
Summary Financials
- Revenue (Q3, 2025)
- ₩3.1B
- Gross profit (Q3, 2025)
- ₩1.2B
- Net income (Q3, 2025)
- (₩5.8B)
- Cash (Q3, 2025)
- ₩7.1B
- EBIT (Q3, 2025)
- (₩4.6B)
- Enterprise value
- $181.0B